J&J vaccine gets conditional approval and Pfizer trial shows great success
The J&J vaccine can now start being used in the general population, while the Pfizer trial shows its vaccine is effective against the B.1.351 variant
01 April 2021 - 15:40
UPDATED 01 April 2021 - 18:34
Johnson & Johnson (J&J) has announced that its single-dose vaccine, being used in a clinical trial for health workers, has received approval for use in SA.
SA Health Products Regulatory Authority (Sahpra) CEO Boitumelo Semete-Makokotlela said, “The registration signals a significant step in the fight against the Covid-19 pandemic.”..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.